Antibody-drug conjugates (ADCs) 定制

抗体药物结合物（ADC）定制

are new-generation anti-cancer immunotherapeutic agents that accurately deliver cytotoxic agents to cancer cells to achieve caner elimination without damaging normal tissues. ADCs carry extremely high potent toxins and their pharmacokinetic properties and safety profile need to be extensively evaluated before deploying to human clinical trials. One crucial aspect in ADC pharmacokinetic (PK) property is the ratio of total and conjugated antibody after certain time period of deployment. This is usually assayed using immuno-colorimetric assay methods such as ELISA. To detect and quantify conjugated antibody, an agent that targets the drug portion of the ADC is desired.

是新一代抗癌免疫治疗剂，能够准确地将细胞毒性药物输送到癌细胞，从而在不损害正常组织的情况下消除癌症。ADC携带极强的毒素，在用于人体临床试验之前，需要对其药代动力学特性和安全性进行广泛评估。ADC药代动力学（PK）特性的一个关键方面是在一定时间部署后总抗体和结合抗体的比率。通常使用免疫比色分析法（如ELISA）进行检测。为了检测和量化结合抗体，需要一种针对ADC药物部分的试剂。

Due to the high potency of ADC toxins, antibodies against these chemical compounds are difficult to develop. Only low dosages of a toxin can be applied for animal immunization and the corresponding immune response is low in small rodents. After devoting a tremendous amount of effort, Creative Biolabs has raised a series of antibodies, collectively anti-drug Abs, against ADC toxin antigens include MMAE, MMAF, DM1, DM4, Calicheamicin, Duocarmycin…. These anti-drug Abs will be valuable assets to facilitate the PK and safety evaluation of newly developed ADCs bearing these drugs.

由于ADC毒素的高效价，很难产生针对这些化合物的抗体。只有低剂量的毒素才能用于动物免疫，而小啮齿类动物的相应免疫反应较低。经过大量努力，Creative Biolabs已经研发出一系列抗体，统称为抗药物抗体，针对ADC毒素抗原，包括MMAE、MMAF、DM1、DM4、卡利霉素、杜卡霉素…。这些抗药物抗体将是有价值的资产，有助于对携带这些药物的新开发ADC进行PK和安全性评估。